Detail Information of Xenobiotics
| General Information of Xenobiotics (ID: XEO00638) | ||||||
|---|---|---|---|---|---|---|
| Xenobiotics Name |
Omapatrilat
|
|||||
| Xenobiotics Type |
Pharmaceutical Agent(s)
|
|||||
| Classification |
Drug in Phase 2 Clinical Trial
|
|||||
| Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=656629"></iframe>
|
 |
||||
| 3D MOL | 2D MOL | |||||
| PubChem CID | ||||||
| DME(s) Modulated by This Xenobiotics | ||||||
| DME(s) Inhibited by This Xenobiotics | ||||||
| Neprilysin (MME) | DME Info | Homo sapiens | [1] | |||
| Xenobiotics-DME Activity Data | ||||||
| Xenobiotics-DME Activity Data | Neprilysin (MME) | DME Info | Ki = 0.009 microM | [1] | ||
| References | ||||||
| 1 | Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem. 2010 Jan 14;53(1):208-20. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.